






PHARMACEUTICAL 2022

Nascent Biotech Inc
Rank 444 of 471



The relative strengths and weaknesses of Nascent Biotech Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nascent Biotech Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 22% points. The greatest weakness of Nascent Biotech Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 268% points.

The company's Economic Capital Ratio, given in the ranking table, is 102%, being 173% points below the market average of 275%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	751	Assets	751
Cost of Goods Sold	0	Liabilities	1,224
Intangible Assets	0	Expenses	2,150
Liabilities, Current	1,224	Revenues	750
Liabilities, Non-Current	0	Stockholders Equity	-473
Other Assets	0	Net Income	-959
Other Compr. Net Income	0	Comprehensive Net Income	-959
Other Expenses	2,150	BaseVar	2,659
Other Liabilities	0	ECR before LimitedLiability	-201%
Other Net Income	442	Economic Capital Ratio	102%
Other Revenues	750		
Property and Equipment	0		
Research and Development	0		
Selling, General and Administrative Expense	0		